INOVIO PHARMA (INO)
$1.64
0.02 (1.22%)
INO Stock Quote Delayed 30 Minutes
This Latest FDA Hold Is a Crushing Blow for Reeling Inovio Stock
Inovio has lost the race for a novel coronavirus vaccine. And INO stock could plummet, given increasing doubts about the company as a whole.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$1.50
Market Cap
60.87M
PE Ratio
-0.41
EPS
-3.9519
Volume (Avg. Vol.)
844,093
Day's Range
$1.47 - $1.68
52-Week Range
$1.47 - $13.44
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and INOVIO PHARMA News
Inovio Stock Still Has Real Promise Despite Faltering in Vaccine Race
INO stock lost steam due to delays in the next stage of its vaccine trials, but there are plenty of reasons why it's still a worthwhile bet.
Speculate on Inovio and Covid-19 Vaccine Developers
After bottoming at $10 earlier this month, investor interest soared in the last week for INO stock and the company's DNA medicine.
Inovio Stock May Very Well Be the Long Shot Vaccine Gamble Worth Taking
Inovio's DNA-based approach gives potential advantages to its Covid-19 vaccine candidate and adds fuel to the volatility of INO stock.
DNA Vaccine Gives Inovio Pharmaceuticals Stock a Long Shelf Life
INO stock traders may be skeptical about Inovio's main Covid-19 vaccine candidate, but the CEO made a convincing case to stay in the trade.
The Compelling Science and the Harsh Risks Behind Inovio Pharmaceuticals
Although vaccine plays are inherently risky, the recent robust rally in INO stock is backed by strong and compelling science.
5 Top Stock Trades for Friday: TWLO, MU, F, INO, X
Twilio, Micron, Ford, Inovio and U.S. Steel were our top stock trades for Friday. So, let's have a look at the charts to see what's new.
At This Point, There’s No Reason to Buy (or Dump) Inovio Pharmaceuticals Stock
Curious why INO stock jumped in recent trading? Overall optimism wasn't the only reason. Read on to gain some perspective on its chances.
INO Stock: Why Inovio Pharmaceuticals Is Rallying 15% Today
Inovio Pharmaceuticals teased investors on Monday that Phase 1 results were just around the corner. INO stock is still rallying. Here's why.
As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating
INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks like an avoid.
Inovio Stock Is Much More Than a Coronavirus Play
Some traders will label INO stock as nothing more than a coronavirus stock. Dig deeper and you'll see that there's much more in the pipeline.
Inovio Stock Is a Longshot Covid-19 Bet
Numerous well-funded coronavirus vaccines are rapidly proceeding through clinical trials. INO stock risks being left behind.
The Key Reasons Investors Should Avoid Inovio Pharmaceuticals Stock
The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a share. That was in late January. By July, the…
Is The Party Over for Inovio Stock? It Depends
Nevertheless, while it's not out of the running just yet, it may be best not to take a gamble with INO stock. Sit on the sidelines for now, and wait for a more compelling entry point.
3 Reasons You Should Still Keep an Eye on Inovio Pharmaceuticals
INO stock is dropping on news that its Covid-19 vaccine candidate is falling behind more established candidates. But science says there may still be a chance.
Inovio Shares Have Been Hot in 2020 but Watch for a Volatile September
Although Inovio shares have skyrocketed this year as part of the vaccine development efforts, the momentum in INO stock may not not be strong.
Inovio Stock Is a Sideshow, Not a Serious Investment
INO stock is putting vaccine news front and center -- in place of strong fundamentals. If you decide to take a chance, be aware -- it's a specuative on
